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Abstract
Motivation: Subtyping cancer is key to an improved and more personalized prognosis/treatment. The
increasing availability of tumor related molecular data provides the opportunity to identify molecular
subtypes in a data-driven way. Molecular subtypes are defined as groups of samples that have a similar
molecular mechanism at the origin of the carcinogenesis. The molecular mechanisms are reflected by
subtype-specific mutational and expression features. Data-driven subtyping is a complex problem as
subtyping and identifying the molecular mechanisms that drive carcinogenesis are confounded problems.
Many current integrative subtyping methods use global mutational and/or expression tumor profiles to
group tumor samples in subtypes but do not explicitly extract the subtype-specific features. We therefore
present a method that solves both tasks of subtyping and identification of subtype-specific features
simultaneously. Hereto our method integrates mutational and expression data while taking into account
the clonal properties of carcinogenesis. Key to our method is a formalisation of the problem as a rank
matrix factorisation of ranked data that approaches the subtyping problem as multi-view bi-clustering.
Results: We introduce a novel integrative framework to identify subtypes by combining mutational and
expression features. The incomparable measurement data is integrated by transformation into ranked
data and subtypes are defined as multi-view bi-clusters. We formalise the model using rank matrix
factorisation, resulting in the SRF algorithm. Experiments on simulated data and the TCGA breast cancer
data demonstrate that SRF is able to capture subtle differences that existing methods may miss.
Contact: kathleen.marchal@intec.ugent.be, siegfried.nijssen@cs.kuleuven.be
1 Introduction
As cancer is a heterogeneous disease, subtyping cancer is key to an impro-
ved and more personalised prognosis and treatment. With cancer genomes,
transcriptomes, and epigenomes becoming increasingly available, one of
the major challenges in cancer research is to use these molecular data to
define clinically or biologically meaningful subtypes.
Successful seminal research on cancer subtyping aimed at grouping
patients based on similarities in their molecular profiles (gene expression)
or extracting expression derived features to optimally classify patients
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according to clinically relevant phenotypes (Perou et al., 2000; Sørlie et al.,
2001; Mischel et al., 2003; Tothill et al., 2008).
With the availability of NGS data, charting cancer genomes, transcri-
ptomes and even epigenomes offers the opportunity to refine subtyping by
taking into account not only the molecular phenotypes (expression) but
also likely driver events (mutations, CNVs, methylations) that are at the
origin of the tumorigenesis (Vogelstein et al., 2013).
Several efforts have been taken to integrate these different molecular
data in order to extract relevant subtypes, for instance Yuan et al. (2011)
and Curtis et al. (2012) relied mainly on combining copy number and
expression data to define subtypes, whereas the more generic models of
Mo et al. (2013), Wang et al. (2014) and Speicher and Pfeifer (2015) use
next to expression and CNV also mutation and methylation data.
The problem of these early approaches, which aim at clustering sam-
ples based on shared CNV and mutational profiles, is that they overlook one
of the major properties of tumorigenesis: its clonality. By directly using
copy number alterations to discriminate between samples they ignore the
fact that CNVs are prevalent in cancerous cells and that many CNVs are
passenger events, not involved in driving the phenotype (> 70%) (Zack
et al., 2013; Sanchez-Garcia et al., 2014). Using passenger events to group
patients might blur the true sample grouping in the data as driving events
are rare compared to passenger events.
The same goes for the sample grouping based on shared somatic muta-
tional profiles. Doing this implicitly assumes that true driving somatic
mutations are frequent across tumor samples, which is because of the
clonality of the carcinogenesis not necessarily true. Because they evo-
lve independently, tumors can trigger the same driver pathways through
mutations in different genes. By focusing only on frequent alterations, rare
events that are very characteristic for a subtype are ignored. In addition,
if similarities between tumor samples are scored using the raw mutation
data, results are mainly driven by the dense data, such as copy number and
gene expression with a negligible contribution from the mutation data.
The most advanced state-of-the-art integrative methods for cancer
analysis do take into account the clonal properties of cancer by searching
for mutational consistency at pathway level rather than at the indivi-
dual gene level. They do so by exploiting the connectivity of mutations
occurring across different tumor samples on an interaction network. An
interaction network here consists of a comprehensive compilation of all
molecular interaction information, available on an organism of interest;
the network is represented as a graph in which the nodes correspond to
genes and the edges to interactions between the genes. Mutations that are
recurrently affecting sets of genes that are closely connected on the inte-
raction network are identified as drivers (Leiserson et al., 2014; Verbeke
et al., 2015; De Maeyer et al., 2016). Hofree et al. (2013) successfully
applied this strategy to use mutation data for subtyping.
Here we introduce a novel analysis framework that combines CNVs
and mutation data with an expression phenotype to identify subtypes while
considering mutational consistency at a pathway level. Because identifying
subtypes and defining the molecular mechanisms (driver pathways) that
drive cancer are confounded (a subtype depends on the molecular mecha-
nism but the molecular mechanisms that one can identify also depends on
how patients are grouped), our method performs the two tasks simultane-
ously. The distinguishing feature of our method is that it is based on ranked
matrix factorisation: all data is represented in ranked form, in which we
identify factors that are used to define subtypes. We propose new methods
to cast the different types of data into a ranked form. We extensively tested
the performance of our method on simulated data. Comparing our method
with other state-of-the-arts on the well-studied TCGA breast cancer data-
set shows how our method is able to grasp the most prominent signatures
in the data that are also retrieved by other methods, but also how it is
able to capture subtle differences that are missed by methods that compare
samples based on global profiles of similarities.
2 The SRF algorithm
An overview is given in Figure 1, details follow. Key processing steps
include 1) diffusing mutation information over an interaction network on
a per sample basis; 2) removing scale differences by applying a rank-based
transformation of the mutation and expression data; 3) applying a model
based on rank matrix factorisation (Le Van et al., 2015) to jointly factorise
the transformed data into a number of ranked factors. Each resulting factor
consists of a subset of samples associated to a subset of expressed and
mutated genes; 4) defining subtypes as combination of ranked factors.
2.1 Transforming input datasets into rank matrices
The first step is to transform the original data into rank matrices.
Transforming transcription data Given a gene expression matrix A ∈
Rl×n, where l is the number of expression genes and n is the number of
tumor samples, its corresponding rank matrix is obtained by sorting each
row’s values from low to high and assigning ranks accordingly (with the
largest rank being assigned to the highest value). That is, all samples are
ranked for each gene. The resulting ranked expression matrix E has the
same size asA and the values in each row are a subset ofσ1 = {1, . . . , n}
(ties all get the lowest rank). Figure 1C shows an example of an expression
matrix A and Figure 1D shows its transformed rank matrix E.
Since this transformation would allow our algorithm to only find over-
expressed genes (genes with an average high rank within a subset of the
samples), we duplicate each row and also assign ranks in the reverse order.
This will allow to find under-expressed genes as well. For example, given
an expression vector g = (−2.0,−3.0, 2.0, 3.0), we obtain both rank
vectors ro = (2, 1, 3, 4) (assigning high ranks to over-expressed genes)
and ru = (3, 4, 2, 1) (assigning high ranks to under-expressed genes). As
a consequence, the resulting rank matrix has twice as many rows as the
original matrix. For ease of exposition we will consider matrix E to have
the same size as A, but the algorithm trivially works on the duplicated
matrix and we will use this extended version in the experiments.
Transforming mutation data and interaction network To transform the
Boolean mutation matrix into a rank matrix, we first map each sample’s
mutation profile to the given interaction network (Vanunu et al., 2010;
Hofree et al., 2013) and apply a network diffusion model. The obtained
diffusion values are then transformed to ranks, so that higher ranks indicate
that a gene is relatively “close” to a mutated gene (for a particular sample).
Figure 1E illustrates this procedure.
That is, let M ∈ {0, 1}m×n be the mutation matrix, where m is the
number of mutation genes and n is the number of samples (as before), and
let G = (V,E) be the interaction network. Applying diffusion (Hofree
et al., 2013) to the n columns of matrix M using G results in a diffusion
matrix B ∈ Rm×n. Finally, by ranking the rows for each column we
obtain the ranked diffusionmatrixD ∈ σm×n2 , σ2 = {1, . . . ,m}, which
we use as input for the next step of the analysis.
2.2 Mining subtypes using rank matrix factorisation
The matrix factorisation model that we introduce aims to jointly factorise
the two transformed rank matricesD andE into a set of k ranked factors,
where k is an integer given by the user. One factor consists of a set of
mutation genes, a set of expressed genes and a set of related samples. To
provide some intuition for our approach, we first present an optimisation
model for a single ranked factor. We then generalise this to k ranked factors
using rank matrix factorisation.
Mining a single ranked factor As mentioned above, a ranked factor
represents a group of samples that are consistently over/under-expressed
in a subset of expression genes and that share the same affected genes in
the ranked diffusion matrix.
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E. Rank genes via network diffusion B. Ranked diffusion matrix D
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F. Two ranked factors (red and blue) identified by SRF
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Fig. 1. SRF illustration. A) Boolean mutation matrix; B) Ranked diffusion matrix derived from the mutation matrix using the network diffusion model shown in Figure E and the parameter
α = 0.7; C) Numeric expression matrix; D) Ranked expression matrix, obtained by ranking column values in each row; E) Illustration how to derive a ranked diffusion vector for tumor
sample P1 using his/her mutation profile and a given interaction network. F) Two ranked factors, represented by C1 , C2 and F , identified by SRF in matricesD and E.
Let P = {1, . . . , n}, M = {1, . . . ,m} and E = {1, . . . , l} be
index sets for tumor samples, mutation genes and expression genes respe-
ctively. A ranked factor is represented by a tuple (P,GM , GE), where
P ⊆ P ,GM ⊆M andGE ⊆ E . Inspired by our ranked tiling work (Le
Van et al., 2014), a ranked factor is obtained by optimising:
argmaxP,GM ,GE
∑
m∈GM ,p∈P (Dm,p − θ1) +
β
∑
e∈GE ,p∈P (Ee,p − θ2) (1)
subject to
∀m ∈M : m ∈ GM → ∑p∈P Mm,p ≥ µ, (2)
where θ1 and θ2 are user-defined thresholds that control how high ranks
in D and E respectively should be to be included in the solution. We
sometimes indicate these thresholds using relative values, i.e., θ1 = a%;
in this case, the absolute threshold is θ1 = a% ∗ n. β is a user-defined
threshold to balance the contributions from the values in the two matrices.
µ indicates the number of patients in which a mutation should be present
in order to be included in the factor.
The objective in Equation 1 selects those rows (mutation and expres-
sion genes) and columns (samples) that together maximise the total sum
of the values in the corresponding cells in the matrices, adjusted by θ1 and
θ2. That is, cells that are lower than the thresholds are penalised and those
that have higher values are rewarded. Equation 2 ensures that each gene
that is selected from the ranked diffusion matrix is mutated in at least one
of the samples present in the selection P . That is, genes that receive a high
rank because they are in the network neighbourhood of genes mutated in
the sample but are never mutated themselves will not be selected.
For example, given the matrices in Figure 1A, 1B, and 1D, and
parameters θ1 = 7, θ2 = 5, β = 1, solving the objective results
in P = {P1, P2, P3, P6}, GE = {E1, E2, E3}, GM =
{M1,M5,M9,M10}. It is clear from the input matrices that this solu-
tion corresponds to an area with relatively high ranks. No more samples
or genes can be added to the solution without decreasing the score. Note
that mutated geneM11 was not selected despite having a high rank as no
samples in the group carry a mutation for this highly ranked gene.
Mining k ranked factors using RMF As Equations (1) and (2) only
provide a way to find a single factor, we here present a variation of rank
matrix factorisation (Le Van et al., 2015) to find a set of k non-redundant
rank factors. To understand this generalisation, let us first reformulate the
problem of finding one factor. Let us note that we can represent the set P
using a 1×n boolean matrixF , withF ∈ {0, 1}1×n, such thatF1,p = 1
iff p ∈ P . Similarly, we can represent the setGM using anm×1Boolean
matrix C1, such that (C1)r,1 = 1 iff r ∈ GM , and the set GE using an
l × 1 Boolean matrix C2, such that (C2)r,1 = 1 iff r ∈ GE .
Let us now denote by Jm,n the m × n matrix in which all cells are
filled with ones, and let the distance between two matrices be defined by
d(A,B) =
∑
ij Ai,jBi,j . Then we can rewrite our earlier problem as
follows in matrix notation:
arg max
C1,C2,F
d(D − θ1Jm,n, C1  F ) + βd(E − θ2Jl,n, C2  F )
(3)
subject to µC1 ≤MFT . (4)
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Here,  denotes the Boolean matrix product; in the Boolean matrix
product the or operator is used instead of the addition operator, i.e., it is
assumed that 1+1 = 1. The constraint ensures that every selected mutated
gene is present in the required number of patients; it uses the traditional
matrix product. This notation makes the connection between our earlier
problem and matrix factorisation clear: we are factorising the ranked data
in a number of Boolean matrices that indicate where values of high rank
can be found.
This new formulation is trivially extended to an arbitrary number
of factors: by allowing that C1 ∈ {0, 1}m×k , C2 ∈ {0, 1}s×k ,
F ∈ {0, 1}k×n for arbitrary k ≥ 1, we obtain a generic matrix factori-
sation setting for any k. Intuitively, in this setting we identify a number of
rectangles in the data; the union of these rectangles is required to contain
the highest ranks. An example is provided in Figure 1F.
To solve the optimisation problem, we follow the algorithm proposed
by Le Van et al. (2015). That is, the SRF algorithm follows an iterative
EM-style scheme, in which first C1 and C2 are optimised given F , and
thenF is optimised givenC1 andC2. We repeat this iterative scheme until
the optimisation score cannot be improved any further. When eitherC1 and
C2 or F is known, it can be shown that the optimisation problem (3) – (4)
is an integer linear programming (ILP) problem. Each such optimisation
problem can be solved optimally. To avoid local maxima, we initialise the
algorithm with a matrix F obtained by performing hierarchical clustering
to cluster the columns into k groups.
As additional contribution, we develop a parallel implementation of
the above algorithm, which makes it scalable to large datasets. Observe
that Equations (3) – (4) allow each row of C1 and C2 to be optimised
independently given F . Further, given C1 and C2, each column of F
can be optimised independently if we relax the inequality in Equation (4),
which puts a constraint on the columns and hence makes them depen-
dent. However, if we require the iterative process to terminate after the
step optimising C1 and C2 given matrix F , we still obtain a very good
approximation upon convergence of the algorithm.
We implemented SRF in OscaR (OscaR Team, 2012) and used Gurobi
as the back-end solver. The implementation is available at: https://
github.com/rankmatrixfactorisation/SRF.
2.3 Deriving cancer subtypes from ranked factors
Ranked factors model groups of tumor samples that are homogeneous
in gene expression as well as in mutations. Hence, if we obtain k non-
overlapping ranked factors, i.e., factors that cover fully disjoint sets of
samples, each factor found is considered to represent a unique subtype.
If the factors overlap in the sample dimension, however, we consider
each group of samples that is covered by a unique combination of ranked
factors to form a subtype. The reason for this is that each combination
of ranked factors represents a different combination of expression and
mutation profiles. In this case, the mutation and expression gene sets of
a subtype are formed by the union of the mutation and expressed genes
(respectively) of all factors in the combination. Section 3 shows examples
of this concept. In practice, we prune subtypes covering fewer samples
than a user-defined threshold, to avoid the discovery of small ‘subtypes’
that are most likely artefacts of noise in the data.
3 Results
3.1 Analysis overview
As input data we use 1) a gene–patient expression matrix describing for
each patient its expression phenotype; 2) a gene–patient mutation matrix
that describes per patient which of the genes carry somatic mutations (see
Figure 1 for an overview of the analysis). To search for pathway level con-
sistency across the tumor samples we use a transformed mutation matrix
obtained by diffusing, per patient, the effect of each mutation over a given
interaction network. In this way, not only genes that are mutated will
receive high relevance scores, but also genes that are close to the muta-
ted genes in the network. Identifying groups of patients with a consistent
mutation profile in this transformed matrix allows searching for mutatio-
nal consistency at the pathway level (Hofree et al., 2013) and accounts for
the clonality of carcinogenesis. Transforming the expression and mutation
matrix to rank matrices is key to removing the scale differences.
A subtype is subsequently defined as a set of tumor samples that share
a similar molecular origin of their disease, i.e., a driver pathway where the
driver mutations occur. The effect of a mutated driver pathway is assumed
to be reflected in the expression phenotype, consistently down- or upregu-
lated compared to the reference, of a subset of the genes downstream in
those samples. Hence, selected genes in the expression data and selected
mutations in the mutation data of the samples in a subtype can be different.
Detecting a subtype is formalised as a complex bi-clustering problem
in which one wants to search for a subset of patients that share both a
similar set of driver mutations and a subset of consistently differentially
expressed genes; given that the clonal phenotypes in cancer are affected in
the same driver pathways, this assumption is reasonable. This clustering
problem is solved by applying rank matrix factorisation (Le Van et al.,
2015) to jointly factorise the ranked mutation and expression matrices into
a number of ranked factors. Conceptually, each resulting factor consists
of a subset of samples associated to a subset of expression and mutation
genes (expression and mutational features) for which the selected samples
have respectively highly ranked expression values and highly ranked rele-
vance scores. Expression and mutational features can, but do not have to
overlap. Whereas a factor represents a group of patients together with their
characteristic features, a subtype is defined as a group of patients covered
by a unique combination of factors. Subtypes can thus mutually overlap in
their characteristic expression and/or mutational features. This overlap in
features between subtypes reflects the fact that subtypes are rarely distinct
but rather represent a continuum of possible alterations. The subtyping
algorithm is dubbed SRF, for Subtyping with Ranked Factors.
3.2 Results on simulated datasets
To test the performance of the method in recovering known subtypes, we
generated datasets in which each subtype was defined as a set of tumor sam-
ples carrying a number of driver genes and a concomitant set of consistently
over- and/or under-expressed genes of which the expression phenotype is
assumed to be triggered by the driver mutations. The data contained 4
subtypes that occasionally shared genes mutated in the same driver path-
ways or genes displaying the same consistent expression. We imposed
the rule that whenever two subtypes share genes mutated in the same dri-
ver pathway(s), they should share a set of consistently expressed genes.
Figures 2A and 2B show an example dataset.
Driver genes were modeled to display mutational consistency at the
pathway level across tumor samples belonging to the same subtype by
selecting the drivers of those patients from a pre-selected set of genes that
are closely connected in a real protein-protein interaction network and
therefore assumed to belong to the same driver pathway. We varied the
size of the driver pathways as well as the mutational recurrency of the
driver genes for the samples within the subtypes to generate datasets (see
Section 4).
For each simulated dataset, we ran our algorithm with varying para-
meter settings. We used two parameters to specify the preferred ranges of
the ranks from the two input matrices, and another to balance the contri-
butions of the two matrices. For each parameter setting, we used SRF to
search for k = 5 subtypes, where the 5th subtype serves as the collection
of tumor samples that have no clear subtype assignment. We initialised the
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A. Mutation data with true subtypes C. Ranked diffusion with mined subtypes 
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Fig. 2. Evaluation on simulated datasets. Panel A–B: Example data with ground truth. The heatmaps show mutation and numeric expression data of a representative simulated dataset, with
a 10% mutational recurrency (meaning that a gene is mutated in at least 10% of the samples in a given subtype) and pathway size of 40. The four ground truth subtypes are marked by
the horizontal and vertical coloured bars above and to the left of the heatmaps. Panel C – D: Results on the data shown in panels A and B. Results obtained by NBS (Hofree et al., 2013),
iCluster+ (Mo et al., 2013), SNF (Wang et al., 2014) and the hierarchical clustering algorithm (hclust), which we used to initialize our model, are shown in the coloured bars above the
heatmaps. The results obtained with SRF are indicated by the four coloured horizontal and vertical bars, just above and to left of the heatmaps; each bar indicates the patients (horizontally)
and genes (vertically) selected by a ranked factor. Panel E: Performance comparison. The three plots denote F1 scores for 1) patient recovery (top), 2) expression gene recovery (middle),
and 3) mutation gene recovery (bottom) for iCluster+, NBS, SRF, and SNF, for simulated datasets of varying driver pathway sizes and mutational recurrencies. Note that NBS does not work
with expression data and we were unable to recover the mutated genes due to a lack of documentation.
algorithm with five sample groups obtained by a hierarchical clustering of
the tumors using the ranked expression data.
After factorising the rank matrices, resulting subtypes containing less
than 4% of the total number of samples were pruned (see Section 4).
Accuracy of the identified subtypes We evaluated the performance of our
algorithm in recovering the known subtypes as well as their characteristic
expression and mutational features. For this we used the F1 score, which
assesses the trade-off between correctly and comprehensively distinguish-
ing between samples, expression genes, and mutational features that truly
belong to the subtypes from those that do not.
To optimise the parameter settings, we calculated F1 scores for dif-
ferent parameter settings and chose the one that resulted in the highest
average score (see Section 4). Then, we used that parameter setting to
evaluate the performance of the algorithm on all the simulated datasets.
Figure 2E shows the F1 scores obtained for different driver pathway
sizes and mutational recurrencies. We can observe that the F1 score of
recovering tumor samples of the simulated subtypes is high and largely
independent of the sizes of the driver pathways and the mutational recur-
rencies. This demonstrates the added value of integrating the expression
data. Further, the F1 scores of recovering mutation and expression genes
relevant to the subtypes are generally high. As expected, the higher the
mutational recurrency, the larger the number of mutated genes that can be
recovered.
Comparison to related work To show that our method performs at least
as well as state-of-the-art subtyping methods, we compared the results
obtained by our method to those obtained with iCluster+ (Mo et al., 2013),
NBS (Hofree et al., 2013) and SNF (Wang et al., 2014), applied on the
same simulated data. Both iCluster+ (Mo et al., 2013) and SNF (Wang
et al., 2014) identify subtypes by jointly clustering the expression and
untransformed mutation data, while NBS (Hofree et al., 2013) exploits
mutational information but does not use expression data.
Results obtained by iCluster+, NBS, SNF and SRF are summarised in
Figure 2E. Our method obtained higher F1 scores than its competitors for
both recovering expression and mutation genes. This is because our model
couples genes, including mutation and expression genes, and patients to
define subtypes and thus explicitly identifies subtype-specific genes. For
iCluster+ and SNF, this is not the case and the selected expression or
mutation genes are thus always the same, irrespective of the subtype.
As a representative example, we illustrate in more detail the results
produced by the different methods on the simulated dataset with a 10%
mutational recurrency and a pathway size of 40 (Figure 2C - 2D). The
figures show that compared to the other methods, our method can discover
overlap between very similar subtypes in both the patient and gene dimen-
sion. In addition, our model is shown to be tolerant to noise: the fifth ranked
factor found by SRF remained empty, revealing that no ‘noisy’ patients
and genes were incorrectly marked as belonging to a subtype.
3.3 Results on the TCGA breast cancer data
To test SRF in a real-world setting, we applied it to the well-studied TCGA
breast cancer dataset. The method was ran as outlined in Section 4. As we
were mostly interested in identifying subtype-specific features, we chose
stringent parameters to only identify subtypes with representative profiles
in terms of expression and mutations Factorising the dataset into k = 8
factors resulted in 13 subtypes. The number of identified subtypes is higher
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Fig. 3. Results of applying SRF (k = 8) on the TCGA breast cancer dataset, which resulted in the 13 subtypes denoted by S1, . . ., S13. For heatmaps in Panels A, C and D: red implies
over-expressed, white neutral, blue under-expressed. Panel A: Expression data. The gene and tumor sample sets corresponding to the eight ranked factors are marked by the vertical and
horizontal colour bars. Each subtype is a unique combination of ranked factors in the tumor sample dimension. Panel B: Mutation data. Samples are ordered as in panel A. Note that although
the method uses the diffused ranked mutation matrix, the shown heatmap corresponds to the Boolean mutation data prior to diffusion. Only mutated genes that belong to any of the factors
are displayed. On panels A and B, the top bar indicates the PAM50 annotation of the samples together with the subtyping results of iCluster+, NBS, SNF, and hierarchical clustering. Panel
C: Expression heatmap of the PAM50 genes. The samples are ordered as in panel A. Panel D: Expression heatmap of the top-10 genes per subtype, i.e., the ten genes having the highest
average ranked scores per subtype. Panel E: KEGG pathway (Kanehisa and Goto, 2000) enrichment results. Mutated genes of the eight factors were tested for pathway enrichment; resulting
−log10 p-values are shown for cancer related pathways that were found to be significantly enriched in at least one of the factors. Panel F: KEGG pathway enrichment analysis for the
top-10 ranked expressed genes of the eight factors. log10 and−log10 p-values are shown for pathways having under- and over-expressed genes respectively.
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Simultaneous discovery of cancer subtypes and subtype features by molecular data integration 7
than the number of factors because subtypes are defined as combinations
of factors (see Section 2.3). The results are visualised in Figure 3.
To validate our subtypes, we tested 1) to what extent the discovered
subtypes corresponded to the PAM50 classification, and 2) to what extent
SRF could further refine it. Figures 3 and 4A show that most subtypes are
enriched in samples with the same PAM50 label (Parker et al., 2009) as
shown in Figure 3A. All samples of the same PAM50 class rarely end up
in a single subtype. The Basal subtype, for example, is divided into two
major subgroups: S10, S12; LumA is divided into S3, S4, S5, S6, S8, S13;
LumB into S1, S2, S5, S9; Her2 into S11 and S7. So our approach does
not only match the PAM50 classification to a large extent, it also further
refines known subtypes.
This high-resolution subtype refinement is a characteristic property of
the method’s intrinsic feature selection. Rather than using global profiles to
group samples, the methods actively searches for combinations of feature
sets (factors) that characterise samples using rather stringent criteria. As a
result differences between expression and mutational profiles are marginal
for some subtypes (e.g., for LumA-related subtypes S3, S4, S8, S13, and
for LumB-related subtypes S7 and S9). Retrospectively, it might have
been possible to merge these subgroups. However, in case of subtypes S10
and S12, carrying samples with the same Basal label, the subtype-specific
mutational and gene expression profiles are quite distinct for the selected
feature sets, corresponding to the brown and pink bars in Figure 3.
Next to the subtypes that have rather homogeneous PAM50 labels
assigned to their samples, subtypes S1, S2, S5 and S9 contain a mixture of
LumA and LumB samples, and S11 contains a mixture of Her2 and LumB
samples. Although some inconsistency between the mere expression-based
PAM50 classification and subtyping protocols based on the integration of
expression and genomic information is to be expected (Curtis et al., 2012),
a closer inspection of the expression and mutational profiles of the subtypes
with mixed PAM50 class membership shows why our method does not
distinguish between, e.g., the selected Her2 and some LumB samples.
That is, the selected LumB samples of subtype S11 contain clear Her2-
related features that distinguish them from other LumB samples, such as an
increased ERBB2 amplification and a more pronounced over-expression
of a characteristic subset of genes.
Our approach towards identifying subtypes together with their features
can only be meaningful if the selected features are biologically relevant.
To assess this, we first tested to what extent the expression features used
to build the PAM50 classifier are amongst our selected features. From the
50 PAM50 features, 49 were present amongst the features selected by our
method after pre-processing (see Section 4). The ranked factors found by
SRF used 2221 features in total, including 48 out of 50 PAM50 features.
To select a smaller representative feature set, the 10 genes with the highest
average ranked score per subtype were selected, resulting in 110 instead
of 2221 features (Figure 3D). Those 110 features contained 8 out of the 48
remaining features of the PAM50 classifier. SRF selects all high-ranking
features, hence the selected feature sets are more redundant than those
used by PAM50, which were designed for classification. If our approach
is to coincide with PAM50, we expect each group of features to be cove-
red by a few PAM genes. Except for one subtype this is indeed the case.
The exception, indicated with the blue row bar in Figure 3D, does not
have a corresponding PAM50 feature. Remarkably this is the feature set
that has the most distinct difference in expression between the two subty-
pes with the same PAM50 Basal label (S10 and S12). Figure 3C shows
how indeed no differences can be observed between Basal subtypes S10
and S12 using the PAM50 features, whereas the subdivision is clear using
the expression-based features selected by our method and shown in Figure
3D. Figure 5 shows how the subtype subdivision of the Basal-like subtypes
and the selection of the corresponding expression features is also driven
by the simultaneous selection of the mutation-based features: S10 and S12
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show clearly distinctive mutational profiles with different mutational fre-
quencies of, e.g., CD9, DRAM1 and E4F1. Interestingly, survival analysis
of these two Basal-like subtypes, despite not being significant due to the
low mortality rate, shows that subtype S12 tends to be more aggressive
than S10 during the first two years (Figure 4B).
To assess whether the selected feature sets belong to known driver
pathways in breast cancer, we did per factor a KEGG pathway enrichment
analysis on respectively the selected mutational and expression features.
Figures 3E and 3F display the enrichment levels for a representative set of
cancer related pathways that were found to be enriched. They also indicate
how each subtype is a composition of different factors and how the factors
overlap in genes and thus also in enriched pathways. For instance, the genes
with a characteristic expression profile in factor 5 (representative for lumA
and B) and factor 4 (representative for basal S10) are enriched in rap1,
ras1 and mapK signaling, but with an anticorrelated expression profile
for the Luminal subtypes versus the Basal one. Figure 3E shows how, as
expected, (Cancer Genome Atlas Network, 2012; Toss and Cristofanilli,
2015; Verbeke et al., 2015), the Basal-related (S10, S12) and Her2-related
subtypes (S11) are highly enriched in p53 signaling and cell cyclewhereas
other subtypes are not. In addition, the Luminal subtypes (LumA and
LumB; S2, S5, S6, S9 and S13) are enriched with cancer pathways known
to be specific for this group: PI3K-Akt signaling pathway (Cancer Genome
Atlas Network, 2012; Verbeke et al., 2015), Estrogen signaling pathway
(Lisa et al., 2013), AMPK signaling pathway (Verbeke et al., 2015).
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Comparison with state-of-the-art methods
To test to what extent our method agrees with state-of-the-art subty-
ping methods, we also ran iCluster+ (Mo et al., 2013), NBS (Hofree et al.,
2013) and SNF (Wang et al., 2014) on the same dataset. Parameter settings
for each of these methods was optimised as explained in Section 4. Figure
3 illustrates how our results compare with those of the other tools in terms
of matching the PAM50 subtyping. SNF and iCluster+, the two integrative
methods that do not use mutational consistency at the pathway level, do
not perform well for some subtypes. For example, SNF could not discern
the heterogeneity of the Luminal samples, which has been known to be the
most heterogeneous breast cancer subtype (Cancer Genome Atlas Netw-
ork, 2012; Curtis et al., 2012), when it clustered all LumA samples and a
large number of LumB samples into one group; iCluster+ could not subdi-
vide the Basal subtype. NBS, which could use mutational consistency at
the pathway level but could not integrate with expression data, could not
distinguish the LumA from the LumB samples. In contrast, our method
can integrate expression data and mutational data at the pathway level and
hence can capture subtle differences that might be missed otherwise.
Comparison with hierarchical clustering We performed a hierarchical
clustering of the tumor samples into clusters, of which the result is anno-
tated by the hclust column bar in Figure 3A. This clustering is also used
to initialise the matrix F of the factorisation in Equation (3). In contrast
to hierarchical clustering, our SRF algorithm identifies clusters (subtypes)
that are highly overlapping and removes noisy samples.
4 Materials and methods
Simulated data Mutational data was generated by first selecting driver
pathways for each of the simulated subtypes. Driver pathways were sele-
cted from the densely connected sub-networks obtained by applying the
InfoMap algorithm (Rosvall and Bergstrom, 2008) implemented in the
igraph (Csardi and Nepusz, 2006) R package on the STRING network
(Szklarczyk et al., 2011) post-processed by Hofree et al. (2013). The sele-
cted driver pathway sizes varied from {20, . . . , 100} genes and each such
gene was assigned a mutational recurrency between 2% and 15%. Pas-
senger mutations were simulated by sampling, for each patient, from a
Bernoulli distribution with p = 0.005 (the average mutational recurrency
we observed in the TCGA breast cancer data). The total number of passen-
gers was chosen such that the total number of mutation genes, including
both drivers and passengers, was 8000, which was approximately equal to
the number of mutation genes used in the TCGA breast cancer data. Each
simulated mutation matrix consists of 8000 genes × 350 patients.
Expression data was simulated as previously described by Le Van
et al. (2015). That is, first background information was generated by
sampling from a mixture of three Gaussians, of which means were uni-
formly sampled from three different ranges, namely, [-5,3), [-3,3] and
(3,5]. Then, over-expressed and under-expressed modules were implanted.
Values within over-expressed and under-expressed modules were sampled
from a Gaussian, with mean uniformly sampled from (3,5] and [-5,-3)
respectively. Per set of driver mutations and thus per subtype, we ensured
that the simulated dataset consisted of at least one set of genes that was
consistently differentially expressed across the samples in the subtype.
To simulate noise in the expression data, we simulated 100 small
expression modules that could be seen as the result of some confoun-
ding factors such as sex and tissue type. The number of rows and columns
of these confounding modules were sampled from a normal distribution,
whose mean was equal to 25% of the medium-sized pattern and standard
deviation was equal to 40% of the mean. Each simulated expression matrix
consists of 4000 genes × 350 patients.
TCGA breast cancer dataset Breast cancer somatic mutation, copy num-
ber alteration (CNA), expression (RNA-Seq v2), and clinical data were
downloaded from the TCGA data portal. Mutational data were converted
to a Boolean mutation matrix. CNA data were analysed using Gistic 2.0
(Mermel et al., 2011) with default settings. This data was then binarised by
considering how genes are classified by Gistic: as either deleted or ampli-
fied. This information was added to the mutation matrix. We restricted our
analysis to mutations and CNVs in genes that also appear in the STRING
network (12232 vertices) prepared by Hofree et al. (2013). Expression
genes were selected based on their differential expression relative to nor-
mal (non-tumor) samples: for each gene a normal distribution was fitted
using the normal expression samples and z-scores were calculated for
the tumor samples. We then evaluated the 5th and 95th percentiles of the
tumor samples. Genes were selected if 1) the p-values for these percentiles
were below 0.001 and 2) their log-fold change relative to the mean normal
expression was at least 2.5. After the filtering steps mentioned above, the
final mutation matrix consisted of 8604 genes×719 patients, and the final
expression matrix of 2472 genes× 719 patients.
Parameter selection To allow for a fair comparison, parameters of the
algorithms were optimised to obtain the best possible results. See the
supplementary document for a more detailed discussion.
Gene feature selection To compare SRF to other methods concerning
the recovery of subtype-specific genes in the simulated datasets, we used
gene feature selection. With our method, it was straightforward to extract
the mutation genes and expression genes representative of the individual
subtypes, as described in Section 2. With iCluster+ (Mo et al., 2013), we
used a quantile cut-off of p = 0.75 to select the important genes according
to the model. With SNF (Wang et al., 2014), we first ordered the genes by
Normalized Mutual Information using the SNF software. We then selected
the top-n expression and the top-m mutation genes, where n and m are
the total number of true expression and mutation genes of the simulated
subtypes respectively. With NBS (Hofree et al., 2013), we could in theory
obtain subtype-specific mutation genes, but were not able to recover them
given the lack of documentation. It is important to note that with both
iCluster+ and SNF, all identified subtypes have the same set of mutation
and expression genes.
Hierarchical clustering SRF requires an initialised matrixF to start from,
which was obtained through hierarchical clustering: we used the hclust
package in R to cluster the columns of the ranked expression matrix into
k groups (with Euclidean distance).
Pruning small subtypes To be more tolerant towards noise, derived subty-
pes that contain less samples than a predefined threshold (less than 4% of
the total number of samples for the simulated datasets) were pruned. Sam-
ples of the pruned subtypes were re-assigned to the remaining subtype that
results in the highest score for the function in Equation 1.
Survival and pathway enrichment analysis Survival analysis was per-
formed using the R survival package. We used time to follow, time to
event and the subtype information produced by our algorithm to calculate
the survival probability. Pathway enrichment analysis was done using the
ClueGo plugin (Bindea et al., 2009) in Cytoscape (Shannon et al., 2003).
5 Discussion
Previous integrative models, such as iCluster+ (Mo et al., 2013) and
SNF (Wang et al., 2014), used between-sample similarities from the sam-
ple’s global expression/mutational profiles to derive subtypes. However,
molecular subtypes are defined by the molecular mechanisms that drive
carcinogenesis. How subtypes are defined thus depends on the features
used to group samples in subtypes. Conversely, the subtypes define which
features are relevant for a certain sample grouping. Hence, subtyping
and feature identification are confounded problems that ideally should
be solved simultaneously.
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In this work we therefore developed SRF, an approach that does so. To
this end we approached the subtyping problem by decomposing patient–
mutation and patient–expression data into ranked factors. A factor here
represents a set of samples for which a set of genes display mutatio-
nal consistency and a (possibly overlapping) second set of genes display
expression consistency. A factor thus is an expressed and mutational fea-
ture set shared by a group of samples, and can be viewed as a bi-cluster
(Madeira and Oliveira, 2004) in respectively the expression and mutation
data that are coupled in the patient dimension. We developed a global
model in the form of matrix factorisation to identify these bi-clusters.
Subtypes are then defined as each patient set that is covered by a unique
combination of ranked factors. As a result subtypes can overlap in the
factors that characterise them, reflecting the fact that subtypes are never
mechanistically completely different, but share common representative
features/driver mechanisms.
Compared to state-of-the-art methods, our method is most related to
Hofree et al. (2013) 1) as it uses a network model to account for pathway
level parallelism between independently evolved tumor samples and 2)
because it extracts features explicitly. However, it is different from Hofree
et al. (2013) by integrating both mutational and expression data.
Compared to related methods, samples without clear-cut signals will
not be assigned to any subtypes. This prevents samples (noisy or hete-
rogeneous samples) from blurring the molecular characteristics that are
representative for a subtype. However, if desired we could assign samples
to the closest subtype identified by our method.
In this paper, we did not consider metabolomics data, as was done in
the work by Tardito et al. (2015). The type of data described in Tardito
et al. (2015) can only be generated for cell lines and not for a tumor biopsy.
It is not available in the context of TCGA or ICGC.
We extensively tested the performance of our method on simulated
data. Testing and comparing our method with other state-of-the-art subty-
ping methods on the well studied TCGA breast cancer dataset shows how
our method is able to grasp the most prominent signatures in the data. In
addition, however, our method is also able to capture subtle differences
that are missed by methods that compare samples based on global profiles
of similarities.
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